Thermo Fisher is the latest company in the biotech sector to announce staff layoffs, with 205 staff set to leave.
The company will cut the jobs in two locations in Alachua, Florida.
The company will start the layoffs in October and continue them until the end of March next year.
The Alachua facility specialized in developing analytics and processes for key viral gene transfer vector systems.
READ MORE: Drug Trial Failure Means Biotechnology Firm Imara Will Lay Off Most Of Its Employees
This includes AAV, adenoviral, herpesviral, lentiviral, and retroviral platforms.
The expansive 95,000-square-foot site also provided quality control testing and manufacturing support for cell and gene therapy clinical trials.
Thermo Fisher has yet to specify the roles affected by these layoffs or provide a reason for the decision.
This trend isn’t exclusive to Thermo Fisher.
Layoffs across the sector
Other major life science companies have also been reducing their workforce this season.
For example, Bristol Myers Squibb recently announced 108 job cuts in New Jersey, following a reduction of 48 positions in the state earlier in April.
A BMS representative stated, “As we progress, our focus remains on executing our long-term business strategy, which involves aligning our resources to optimally support our operational structure and evolving portfolio.
We deeply value our employees’ contributions and are committed to assisting them throughout this transition.”
In a separate development, Emergent BioSolutions is parting ways with approximately 400 staff members across various business segments.
The company recently announced a shift in focus from contract manufacturing to concentrate on its primary products, including medical countermeasures and Narcan.
